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Oligodendrogenesis and oligodendrocyte precursor maturation are essential processes
during the course of central nervous system development, and lead to the myelination
of axons. Cells of the oligodendrocyte lineage are generated in the germinal
zone from migratory bipolar oligodendrocyte precursor cells (OPCs), and acquire
cell surface markers as they mature and respond specifically to factors which
regulate proliferation, migration, differentiation, and survival. Loss of myelin underlies
a wide range of neurological disorders, some of an autoimmune nature—multiple
sclerosis probably being the most prominent. Current therapies are based on
the use of immunomodulatory agents which are likely to promote myelin repair
(remyelination) indirectly by subverting the inflammatory response, aspects of which
impair the differentiation of OPCs. Cells of the oligodendrocyte lineage express and
are capable of responding to a diverse array of ligand-receptor pairs, including
neurotransmitters and nuclear receptors such as γ-aminobutyric acid, glutamate,
adenosine triphosphate, serotonin, acetylcholine, nitric oxide, opioids, prostaglandins,
prolactin, and cannabinoids. The intent of this review is to provide the reader with a
synopsis of our present state of knowledge concerning the pharmacological properties
of the oligodendrocyte lineage, with particular attention to these receptor-ligand (i.e.,
neurotransmitters and nuclear receptor) interactions that can influence oligodendrocyte
migration, proliferation, differentiation, and myelination, and an appraisal of their
therapeutic potential. For example, many promising mediators work through Ca2+
signaling, and the balance between Ca2+ influx and efflux can determine the temporal
and spatial properties of oligodendrocytes (OLs). Moreover, Ca2+ signaling in OPCs
can influence not only differentiation and myelination, but also process extension and
migration, as well as cell death in mature mouse OLs. There is also evidence that
oligodendroglia exhibit Ca2+ transients in response to electrical activity of axons for
activity-dependent myelination. Cholinergic antagonists, as well as endocannabinoid-
related lipid-signaling molecules target OLs. An understanding of such pharmacological
pathways may thus lay the foundation to allow its leverage for therapeutic benefit in
diseases of demyelination.
Keywords: oligodendrocyte, GABA, glutamatergic, cholinergic, muscarinergic, opioids, nuclear receptor,
regeneration
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INTRODUCTION
The central nervous system (CNS) relies on a network of
neuronal cells to transmit electrical impulses known as action
potentials along the axon. A lipid-rich membrane, myelin
(Virchow, 1854), insulates the axon and allows for rapid
conduction of such impulses and proper delivery to the target
cell (Hartline and Colman, 2007). Schwann cells supply myelin
for the peripheral nervous system (PNS), whereas in the CNS,
oligodendrocytes (OLs; Iglesias-Rozas and Garrosa, 2012) are
responsible for myelin production, and are generated in the
germinal zone frommigratory bipolar oligodendrocyte precursor
cells (OPCs; Grinspan, 2002; Brazel et al., 2003). Myelinating
OLs not only provide trophic support for axons, but also release
lactate through the monocarboxylate transporter 1 which is
then utilized by axons for mitochondrial adenosine triphosphate
(ATP) generation (Saab et al., 2013). The migration of OPCs is
influenced by receptor-ligand adhesions with the extracellular
matrix, such as integrins, and signaling molecules (Soliven,
2001) which may provide a critical link between neuronal
cell activity and OPCs. Cells of the OL lineage acquire cell
surface markers with maturation and respond specifically to
factors which regulate proliferation, migration, differentiation,
and survival (Figure 1).
Impairment of one or more of these processes can lead
to myelin degeneration, dysfunction or loss in nerve signal
conduction and ultimately, nerve deterioration (Felts et al.,
1997; Mensch et al., 2015). Loss of myelin results in a
wide range of neurological disorders, including reduced
motor function, impaired cognitive abilities, and vision
problems. Demyelinating diseases of the CNS include
multiple sclerosis (MS), acute disseminated encephalomyelitis,
neuromyelitis optica, transverse myelitis, central pontine
myelinolysis and leukodystrophy, while those of the PNS
include chronic inflammatory demyelinating polyneuropathy,
Guillain-Barré syndrome and Charcot-Marie-Tooth disease
(http://www.neurodegenerationresearch.eu/about/what).
Perinatal white matter (WM) injury, or periventricular
leukomalacia, is the most common cause of brain injury in
premature infants and is the leading cause of cerebral palsy.
Late OPCs exhibit selective vulnerability in this last pathology
(Back et al., 2007). Contrary to what was once believed, we
now know that the mammalian CNS can undergo neurogenesis
and gliogenesis, re-establishing axon-glial interactions needed
for remyelination (Compston, 2002). Importantly, cells of the
OL lineage express and respond to a broad range of receptor-
ligand pairs, in particular neurotransmitters and nuclear
receptors (NRs) like glutamate (Glu), γ-aminobutyric acid
(GABA), ATP, serotonin, acetylcholine (ACh), nitric oxide
(NO), opioids, prostaglandins, prolactin (PRL), cannabinoids
and the superfamilty of NRs (steroid hormones, sex hormones,
oxysterols, vitamin D3, thyroid hormone (TH), retinoic acid,
fatty acid amides). Clearly, knowledge about the OL lineage
has increased greatly over the past few years, with attention
shifting towards manipulation of that lineage for therapeutic
purposes. This review is intended to provide an overview
of current knowledge on the pharmacological properties of
the OL lineage, with particular attention to these receptor-
ligand interactions and how they may influence OL migration,
proliferation, differentiation, and myelination, together with an
appraisal of their therapeutic potential. In this context, a number
of mediators work through Ca2+ signaling, with the balance
between Ca2+ influx and efflux determining the temporal and
spatial properties of OLs. Moreover, Ca2+ signaling in OPCs
can influence not only differentiation and myelination, but also
process extension and migration, as well as cell death in mature
mouse OLs. Research until now has identified cholinergic
antagonists, as well as endocannabinoid-related lipid-signaling
molecules with the ability to target OLs. Understanding the
above-mentioned relationships may help to delineate additional
new therapeutic avenues for remyelination/repair. The main
systems examined are briefly summarized on Figure 2.
MATERIALS AND METHODS
The literature search for this review was carried out according to
the PRISMA (Preferred Reporting Items for Systematic Reviews
andMeta-analyses) guidelines as they apply to systematic reviews
(Moher et al., 2010). The search strategy is given after Conclusion
and Perspectives. A total of 387 manuscripts were retrieved.
Exclusion criteria are given in Figure 3. In all, 279 articles
remained for this review.
GABAergic Signals
GABA is the main inhibitory neurotransmitter in adult brain
(Koós and Tepper, 1999; Markram et al., 2004; Takesian and
Hensch, 2013), where it binds two main receptor types: fast
hyperpolarizing ionotropic GABAA receptors and metabotropic
GABAB receptors.
GABA participation in inhibitory neurotransmission is
limited in adulthood, as in many brain regions during early
development activation of GABAA receptors excites neurons
through activation of Na-K-Cl cotransporter1 (NKCC1)
symporter which increases extracellular K+ and a depolarizing
efflux of Cl−, in turn triggering Ca2+ influx (Dzhala et al., 2005).
Similarly OPCs, but not OLs, express NKCC1. Muscimol,
a GABAA agonist, increases intracellular Ca2+ [Ca2+]i
protecting cultured OLs following withdrawal of culture
medium supplements (N1, biotin, platelet-derived growth factor,
PDGF;Wang et al., 2003). Using the GABAA receptor antagonist
pentylentetrazole, Mensch et al. (2015) showed a subtle increase
in the number of OLs and a 40% increase in the number of
myelin sheaths in the zebrafish ventral spinal cord. OLs may
express also GABAB receptors, whose activation increases
proliferation and migration of OPCs via a negatively coupled
adenlyl cyclase signaling pathway. The GABAB receptor agonist
baclofen significantly reduced cyclic adenosine monophosphate
and adenlyl cyclase and led to an increase in OPC migration
(Luyt et al., 2007).
Glutamatergic Signals
Glu, the principal excitatory neurotransmitter, acts on
postsynaptic ionotropic and G-protein-coupled metabotropic
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FIGURE 1 | Stages of oligodendrocyte maturation toward the oligodendroglial lineage: oligodendrocyte precursor cells (OPCs), preoligodendrocytes
(pre-OLs), immature oligodendrocytes (OLs) and myelinating mature OLs. These stages are identified by their increasingly complex morphology and
expression pattern of well-defined markers. Two basic helix-loop-helix transcription factors, Olig1 and Olig2, play essential roles in determining the oligodendroglial
lineage and in the generation and maturation of OLs (Zhou et al., 2000; Lu et al., 2001). The localization of Olig1/2 is observed in the nucleus of OPCs during
development; however, although Olig2 remains in the nucleus of OPCs in the adult mouse (Arnett et al., 2004), Olig1 translocation into the cytosol highly correlates
with the differentiation of OLs, the termination of the cell cycle and Olig1 phosphorylation (Niu et al., 2012). CNPase, 2′,3′-cyclic nucleotide 3′-phosphodiesterase;
GalC, galactocerebroside C; MAG, myelin associated glycoprotein; MBP, myelin basic protein; MOG, myelin oligodendrocyte glycoprotein; PDGF-Rα,
platelet-derived growth factor receptor; PLP, proteolipid protein.
(mGluR) receptors. The former comprise the ligand-gated
ion channel N-methyl-D-aspartate (NMDA), alpha-amino-
3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) and
kainate receptor subtypes (Dingledine et al., 1999; Swanson et al.,
2005). These receptors are expressed by glial cells in both gray
matter (Jabs et al., 2005; Matute, 2006; Bakiri et al., 2009) and
WM (Matute, 2010). Virtually all neurons expressing ionotropic
Glu receptors are sensitive to excitotoxic injury (Choi, 1988;
Lipton and Rosenberg, 1994). Glu is toxic also for astrocytes
(Haas and Erdö, 1991) and OLs (Matute et al., 1997; McDonald
et al., 1998).
Cells of the OL lineage express functional AMPA and
kainate-type Glu receptors throughout their development and
across species, including man. NMDA receptors on both
immature and mature OLs can be activated during injury
(Káradóttir et al., 2005; Salter and Fern, 2005; Micu et al.,
2006). OLs express as well all three groups of metabotropic Glu
receptors in a developmentally-regulated fashion (Deng et al.,
2004; Spampinato et al., 2015). In addition to astrocytes, OLs
also express glutamate transporters, mainly the Glu aspartate
transporter (GLAST; EAAT1 in the modern nomenclature). The
neuronal transporter, termed excitatory amino acid carrier 1
(EAAC1; EAAT3 in the modern nomenclature), is present in a
subpopulation of adult OPCs (Domercq et al., 1999).
Primary cells of the OL lineage are highly vulnerable to a
form of excitotoxic injury mediated by a transporter-related
mechanism involving inhibition of cystine uptake, glutathione
depletion and oxidative stress (Oka et al., 1993). Alterations in
Glu homeostasis in WM may thus determine injury to OLs and
myelin. Prolonged activation of GluRs is toxic to primary OLs
in vitro and in vivo (Matute et al., 1997; McDonald et al., 1998; Li
and Stys, 2000).
Activation of AMPA and kainate receptors on microglia leads
to the release of tumour necrosis factor-α (TNF-α), which can
potentiate Glu neurotoxicity and kill OLs, destroy myelin and
damage axons (Merrill and Benveniste, 1996). Inflammatory
cytokines like TNF-α and interleukin-1β released by reactive
microglia can impair Glu uptake and trigger excitotoxic OL
death (Takahashi et al., 2003). Indeed, inhibiting the expression
and function of Glu transporters in axonal tracts is sufficient to
induce OL loss and demyelination (Domercq et al., 2005). AMPA
receptors on OLs lack GluR2 subunits, suggesting a higher Ca2+
permeability than for these cells in gray matter (Matute, 2006).
Myelin regeneration can occur spontaneously, even
in pathological conditions such as MS. Using an in vivo
remyelination model, Gautier et al. (2015) demonstrated that
demyelinated axons are electrically active and generate de novo
synapses with recruited OPCs which, early after lesion induction,
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FIGURE 2 | Expression of neurotransmitter and other signaling receptors during oligodendrocyte maturation. ADP, adenosine diphosphate; ATP,
adenosine triphosphate; β-ARs, β-adrenoreceptors; DA, dopamine; GABA, γ-aminobutyric acid; GLU, glutamate; NE, norepinephrine; 5-HT, 5-hydroxytryptamine;
NO, nitric oxide.
sense neuronal activity by expressing AMPA/kainate receptors.
Furthermore, blocking neuronal activity, axonal vesicular release
or AMPA receptors in demyelinated lesions results in reduced
remyelination. In the absence of neuronal activity there is a
∼6-fold increase in OPC number within the lesions and a
reduced proportion of differentiated OLs. These findings reveal
that neuronal activity and release of glutamate instruct OPCs to
differentiate into new myelinating OLs that recover lost function
(Gautier et al., 2015).
Another mechanism of Glu action on OPC differentiation
involves activation of specific NMDA receptor subunits, as
NMDAR1 and NMDAR2A protein levels increase during
differentiation whereas NMDAR2B and NMDAR3 levels
decrease (Sawada et al., 1996; Cavaliere et al., 2012). These
authors showed that activation of NMDA receptors during OLs
differentiation elevated cytosolic Ca2+ levels and promoted
myelination when co-cultured with neurons. NMDA receptors
on multipotent stem cells promote maturation of OLs and favor
myelination through production of reactive oxygen species;
levels of the latter correlate with degree of differentiation, an
effect negatively modulated by the NADPH inhibitor apocynin
(Cavaliere et al., 2012). Interestingly, NMDA receptors are
expressed in clusters on OL processes, whereas AMPA and
kainate receptors are diffusely located on the cell somata
(Káradóttir et al., 2005; Salter and Fern, 2005; Micu et al., 2006).
Activation of mGlu4 on astrocytes appears to be involved
in sparing OLs from excitotoxic challenge (Spampinato et al.,
2015), hinting that they may be a novel target to protect
from demyelination. Other pharmacological approaches, such
as ionotropic Glu receptor antagonists, increase OL survival
but have no effect on neuroinflammation (Pitt et al., 2000).
A close interplay between astrocytes and OLs is supported by
the observation that kainate-induced toxicity is attenuated by
stimulation of mGlu4 receptors only in a mixed culture of OLs
and astrocytes; the mGlu4 receptor agonist L-AP4 does not act
directly on OLs. Activation of mGluRs, including mGlu4 on
astrocytes, is reported to be neuroprotective (Yao et al., 2005;
Corti et al., 2007).
Soluble factors released by astrocytes might mediate
L-AP4-increased OL viability. Transforming growth factor
beta 1, which increases upon L-AP4 treatment, protects OLs
from kainate-induced toxicity (Spampinato et al., 2015),
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FIGURE 3 | Study inclusion flowchart. This depicts the methodology for
search and collection of relevant articles for this review, following PRISMA
guidelines.
an effect attenuated by a neutralizing anti-transforming
growth factor beta 1 antibody. Factors that contribute to Glu
homeostasis include glutaminase, which is present in OLs and
microglia (Domercq et al., 1999; Werner et al., 2001). Non-toxic
concentrations of Glu acting at kainate receptors can induce
OL death also by sensitizing these cells to complement attack
(Alberdi et al., 2006), an action mediated by proteolysis of
complement protein C5 to generate the potent chemoattractant
C5a which interacts with its G-protein-coupled receptor C5aR
(CD88; Ward and Newman, 1969) on OLs and other CNS cells
(Nataf et al., 2001).
In conclusion, factors that evoke an increase in [Ca2+]i can
regulate cell proliferation, survival, growth and differentiation
or induce a pathological condition, as a function of OL
developmental stage.
Purinergic Signals
ATP is a co-transmitter released with other ‘‘classical’’
transmitters and activates ionotropic (P2X) and metabotropic
(P2Y) receptors (Ralevic and Burnstock, 1998; North, 2002). In
the CNS, ATP can be released by neurons and glia via membrane
transporters, vesicles, and ATP-permeable channels (Fields
and Stevens, 2000; Ballerini et al., 2002; Coco et al., 2003).
OPCs express several ionotropic (P2X1,2,3,4,7) and metabotropic
(P2Y1,2,4) receptors, with P2X7 and P2Y1 receptors being the
main ionotropic and metabotropic P2 receptors, respectively
(Agresti et al., 2005). ATP and adenosine diphosphate (ADP)
may regulate OPC functions through P2Y1 receptors. For
example, ATP and ADP (the P2Y1-specific agonist ADPbS)
induced OPC migration. Moreover, ATP and ADP inhibited
OPC proliferation induced by PDGF in purified cell cultures
and in cerebellar tissue slices (Agresti et al., 2005). These effects
of ATP and ADP on cell migration and proliferation were
being blocked by a P2Y1 antagonist (MRS2179). P2Y1 receptors
localize to NG2-labeled OPCs in the developing rat brain
(Agresti et al., 2005).
OPC migration involves the interactive effects of growth
factors, chemokines, integrins, neurotransmitters, and
extracellular matrix molecules (Decker et al., 2000; Tsai
and Miller, 2002). PDGF and basic fibroblast growth factor
induce OPC migration in vitro, acting mainly as chemotactic
stimuli (Armstrong et al., 1990; Milner et al., 1997), while ATP
enhances the migration of OPCs by stimulating predominantly
random motility and to a lesser extent, chemotaxis (Agresti
et al., 2005). These authors propose that ATP, acting mainly at
P2Y1 receptors, may be important in stimulating OPC migration
along a chemotactic gradient towards specific sites. However,
under pathological conditions the P2X7 receptor is involved
in OPC migration (Feng et al., 2015). High concentrations
of ATP or the P2X7 receptor agonist BzATP increased the
number of migrating OPCs in vitro, while pre-treatment
with the P2X7 receptor antagonist oxidized ATP decreased
the promotive effect. This effect appeared to depend on
Fyn, a member of the Src family of kinases (Feng et al.,
2015).
Differentiated OLs in vitro express functional P2X and P2Y
receptors, which can act as mediators of axono-oligodendroglial
communication during myelination (Alberdi et al., 2005). P2X1
and P2X3 receptors produce rapidly desensitizing currents
whereas P2X7 receptors, as well as P2X2 and P2X4 receptors, may
undergo a conformational change which results in formation of
a large pore upon prolonged exposure to ATP (Khakh et al.,
1999). ATP signaling can directly trigger OL excitotoxicity via
activation of Ca2+-permeable P2X7 receptors, leading to WM
lesions reminiscent of MS plaques (Walz et al., 1993; Butt, 2006).
Serotoninergic Signals
Serotonin (5-hydroxytryptamine, 5-HT) plays critical roles in
early neural development, being involved in neuronal cell
differentiation and migration, axonal growth and pathfinding,
dendritic arborization, synaptogenesis, circuit formation, and
neuronal plasticity (Daubert and Condron, 2010). Mice with
either 5-HT transporter (Esaki et al., 2005) or monoamine
oxidase A gene deficiencies (Cases et al., 1996) show disrupted
primary somatosensory cortical organization.
Depression is reported to be accompanied by myelin and
OL abnormalities (Yamazaki et al., 2007), including a significant
reduction in myelin basic protein (MBP) expression in multiple
brain areas of post-mortem samples from depressed patients
(Honer et al., 1999; Taylor et al., 2004; Regenold et al.,
2007). Further, Aston et al. (2005) found in temporal cortex a
down-regulation of both OL development-related and myelin
formation-related genes.
Manipulation of 5-HT levels in postnatal day 6–8 rats with
selective 5-HT reuptake inhibitors (SSRIs; Xu et al., 2004) or
p-chlorophenylalanine-induced 5-HT depletion (Persico et al.,
2000) leads to disorganized cortical barrel fields, abnormal social
behavior, callosal myelin malformation, and OL pathology. 5-HT
receptor subtypes 1A and 2A have been found in OL lineages and
to co-localize with developmental lineage-selective markers (Fan
et al., 2015). Exposure to 5-HT not only disturbed development
of OLs with aberrant process outgrowth and reduced MBP
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and proteolipid protein (PLP) expression, but even caused a
developmentally-dependent cell death at the highest doses via
5-HT2A. By means of a neuron-OL myelination co-culture
model, Fan et al. (2015) demonstrated that 5-HT exposure alters
the localization and regular space patterns of the paranodal
contactin-associated protein (Caspr), but did not cause OL
death or reduce OL density. These authors suggested that 5-HT
exposure induces a diffuse and enlarged pattern affecting other
axon-derived factors for myelination.
It is tempting to speculate that manipulation of 5-HT
levels affects OL development and myelination, thereby
contributing to the altered neural connectivity seen in SSRI-
treated animals (Simpson et al., 2011). SSRIs (Loughhead
et al., 2006) and serotonin/norepinephrine reuptake inhibitors
(Wang et al., 2014), which are widely prescribed for major
depression in pregnant women, are able to cross the placenta
and reach fetal compartments. Animal data suggest that
extracellular 5-HT levels in CNS could rise up to 20-fold
upon SSRI exposure (Tao et al., 2000). Such high levels of
extracellular 5-HT may adversely affect OL development
and/or myelination, perhaps contributing to altered neural
connectivity seen in depression and in autism spectrum
disorders. Further, the late maturation of human myelin,
especially in prefrontal cortex has potential implications in the
treatment of humans with SSRIs in early adolescence or young
adulthood.
Spinal cord injury (SCI) causes secondary damage involving
OL cell death and axon demyelination. SSRIs like fluoxetine
improve neurological outcome in animal models of SCI by
inhibiting microglia activation which can cause the death of
OLs. The underlying mechanism involves inhibition of p38
mitogen-activated protein kinase (p38-MAPK) and pro-nerve
growth factor expression. In addition, fluoxetine can attenuate
Ras homolog gene family member A activation, decrease the level
of phosphorylated c-Jun and alleviate activation of caspase-3.
Fluoxetine may thus be a novel therapeutic agent for acute SCI
in humans (Lee et al., 2015).
Catecholaminergic Signals
The brain’s principal catecholamine neurotransmitters include
3,4-dihydroxyphenethylamine (dopamine, DA) and 4,5-
β-trihydroxyphenethylamine (norepinephrine, NE). DA
controls locomotor activity, cognition, emotion, positive
reinforcement, food intake, and endocrine regulation (Missale
et al., 1998). Neuropsychiatric and motor function disorders like
schizophrenia and Parkinson’s disease (PD) are often linked to
abnormal DA signaling (Civelli et al., 1993). DA receptors can
be divided into two main groups: D1-like (D1 and D5; Sunahara
et al., 1991; Tiberi et al., 1991) and D2-like (D2, D3, D4; Sokoloff
et al., 1990; Van Tol et al., 1991; Sawada et al., 1998).
D2 and D3 receptors are expressed by differentiated rat
cortical OLs (Rosin et al., 2005), although little is known about
their role(s) in OL biology. Cortical OLs in vitro are vulnerable to
receptor-independent Glu-induced cell death (Oka et al., 1993;
Rosin et al., 2004) which involves oxidative stress, inhibition of
cystine uptake and depletion of intracellular stores of reduced
glutathione (Murphy et al., 1990). Glu-induced death of cortical
OLs was protected by co-treatment with either D2 or D3 agonists
(Avenell et al., 1999) and appeared to involve quinpirole-sensitive
activation of MAPK/extracellular signal-regulated kinase and
oxidative stress (Rosin et al., 2005). The protective effect of
quinpirole was fully attenuated by the D2 receptor antagonist
L-741,626 (Avenell et al., 1998). Intriguingly, oxygen/glucose
deprivation up-regulated expression of D2 and D3 receptors
over a much shorter time scale (2 h) compared to the time
needed to induce injury (18 h; Rosin et al., 2005). Cellular
responsiveness to oxygen/glucose deprivation injurymay depend
on the state of OL maturation (Deng et al., 2003). As D3
receptors are expressed in differentiating OLs before terminal
maturation, it is possible that DA plays a role in OL lineage
differentiation and/or the formation of myelin by mature OLs
(Bongarzone et al., 1998).
NE is a hormone and neurotransmitter that affects brain
areas involved in vigilant concentration. NE underlies the
fight-or-flight response, directly increasing heart rate, triggering
the release of glucose from energy stores, and increasing
blood flow to skeletal muscle. OPCs express functional α-
and β-adrenoreceptors (ARs). Response to NE is enhanced
following OPC maturation into differentiated OLs: α1A-ARs
induce phosphoinositide hydrolysis without effecting OPC
proliferation, while β-ARs increase intracellular cyclic AMP
and inhibit their proliferation (Cohen and Almazan, 1993;
Ghiani et al., 1999). The effects of NE can be mirrored
by molecules like phorbol esters, which mimic the action
of second messengers, leading to inhibition of terminal
differentiation of OLs and block of myelin-specific protein
expression (Baron et al., 1998). Protein kinase C activators
work at a later stage of differentiation to facilitate myelination
(Vartanian et al., 1986; Asotra and Macklin, 1993; Yong et al.,
1994).
Cholinergic Signals
ACh was the first identified neurotransmitter, and has important
roles in neuron-glia signaling (Wessler et al., 2001). ACh
can act on different tissues and cell types (Proskocil et al.,
2004; Kawashima and Fuji, 2008) to modulate growth, survival,
differentiation, and apoptosis (Eglen, 2005). While muscarinic
cholinergic receptors can promote neuronal cell differentiation
during neurogenesis (Lauder, 1993; Tata et al., 2003; Salani
et al., 2009), nicotinic cholinergic receptors affect inflammation
centrally by modulating microglial release of cytokines, and
peripherally through immune system cells (Tracey, 2002; De
Simone et al., 2005; Kawashima and Fuji, 2008). Several glial
cell populations, including OLs express ACh receptors (Murphy
et al., 1986; Van Der Zee et al., 1993; Rogers et al., 2001; Loreti
et al., 2007).
Stimulation of muscarinic receptors on OLs (Larocca and
Almazan, 1997; Molina-Holgado et al., 2003) activates MAPK
and increases inositol trisphosphate levels and Ca2+ waves
(Ritchie et al., 1987; Kastritsis and McCarthy, 1993; Cohen and
Almazan, 1994; Larocca and Almazan, 1997). Rat OPCs express
all muscarinic receptors with particular abundance of M3, while
mature OLs have barely detectable levels of all subtypes except
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for M2, suggesting a dynamic regulation during OL maturation
(De Angelis et al., 2011). Furthermore, specific physiological
role(s) may be inferred from their diverse cellular distribution:
M1 and M3 are localized in cell bodies and processes while M4 is
found only in the cell body (De Angelis et al., 2011).
Muscarinic receptors can affect OPCs proliferation. For
example, carbachol induces proliferation via both muscarinic
and nicotinic cholinergic receptors (Peralta et al., 1987; Cohen
et al., 1996). De Angelis et al. (2011) used selective muscarinic
antagonists to discriminate receptor subtype involved in OPC
proliferation. These authors showed that only M1, M3 and M4
antagonists were able to reduce proliferation. Indeed, gallamine
did not affect proliferation via M2 antagonism. In contrast,
M2 activation by arecaidine influenced OPC survival in a
dose-dependent manner, showing toxic effects, indicating the
involvement of M2 in OPC survival (De Angelis et al., 2011).
ACh receptors have been extensively studied in terms of
expression levels of myelin proteins (i.e., MBP, PLP, and
the myelin and lymphocyte protein). Muscarine treatment
of cultured OPCs and mature OLs decreased expression
of MBP (De Angelis et al., 2011), although the drug’s
effect on expression of other myelin proteins was equivocal,
suggesting a specific role of muscarinic activation in MBP
production and terminal differentiation of OLs (De Angelis
et al., 2011). However, it should be kept in mind that MBP
is a marker for mature myelinating and non-myelinating
OLs but not OPCs. Given their ability to control glial cell
proliferation, M1, M3 and M4 muscarinic receptor antagonists
(Felder et al., 2000; Wess, 2004; Langmead et al., 2008;
McArthur et al., 2010) might be useful in the treatment
of brain tumors such as gliomas and oligodendrogliomas
(Guizzetti et al., 1996; Loreti et al., 2007; Tata and Calogero,
2010).
Muscarinic drugs could also find utility in stem cell
therapy, based on their capability to regulate myelin repair
in demyelinating diseases such as MS (Goldman et al., 2012).
Abiraman et al. (2015), using OPCs isolated from human fetal
forebrain showed that the potent, non-selective muscarinic
receptor agonist oxotremorine-M reduces OL differentiation.
In contrast, the selective M3 antagonist darifenacin (Moriya
et al., 1999) failed to influence OL differentiation, suggesting
that M3 receptors are not expressed by human OPCs and/or
that darifenacin does not act as an inverse agonist. However,
when human OPCs were cultured with fetal human neuronal
re-aggregates, ACh release from ACh+ neurons delayed
OPC differentiation in a darifenacin-sensitive manner,
suggesting that M3 antagonism could promote human OL
differentiation (Abiraman et al., 2015). Further, solifenacin, a
blood-brain barrier-permeable analog of darifenacin, promoted
differentiation and myelination in neonatal mice transplanted
with human OPCs (Maruyama et al., 2008). Collectively,
these findings encourage the view that such pharmacological
treatments could one day serve to induce resident OPC
differentiation and improve outcome in demyelinating
diseases such as MS, where OL differentiation is impaired
(Franklin and Kotter, 2008; Franklin and ffrench-Constant,
2008).
Nitric Oxide
NO is a gaseous, cell-penetrant neurotransmitter. Under
physiological conditions NO is present in the picomolar-
nanomolar range in the CNS (Hall and Garthwaite, 2009),
where it is generated by neuronal NO synthase (nNOS)
in response to NMDA receptor-triggered rises in [Ca2+]i
(Hall and Garthwaite, 2009). NO stimulates specialized
guanylyl cyclase-coupled receptors to generate cyclic GMP
(Garthwaite, 2008; Hardingham et al., 2013). Neurons
and astrocytes are the principal targets of NO, although
neuronally-derived NO may also act on the microvasculature
to regulate blood flow (Yang et al., 2003). NO, superoxide,
and hydrogen peroxide regulate MBP phosphorylation
which contributes to neuron–oligodendrocyte signaling by
promoting stability of the myelin sheath (Atkins and Sweatt,
1999).
The cerebellum is an important area for motor control
and one in which NO-cyclic GMP signaling contributes to
synaptic plasticity and other phenomena (Garthwaite, 2008;
Contestabile, 2012). Myelination in the rat cerebellum begins in
the central WM at around postnatal day 6 (P6) and proceeds
along the axial core of the lobules to appear in the internal
granule cell layer 4–6 days later (Gianola et al., 2003). The
development of OL NO-reactivity between P3 and P8 would
be consistent with its role in this process. In cortical cell
cultures, NO and cyclic GMP enhance arborization of OLs.
Compounds that increase NO activity promote OL growth
and maturation (Garthwaite et al., 2015). Moreover, NO can
coordinate axon myelination with neuronal activity during
development and contribute to adaptive changes in adult
myelination (Garthwaite et al., 2015). However, in OLs high
NO concentrations can inhibit mitochondrial respiration and
contribute to oxidative/nitrosative stress through peroxynitrite
formation that induces uncontrolled MBP phosphorylation
(Atkins and Sweatt, 1999), which may render the myelin
sheet less stable. Therefore, anti-oxidant and mitochondria
protective therapeutic strategies may be beneficial in MS,
in particular in early stages of the disease (Lassmann,
2011).
Opioids
Neural stem cells (NSCs) and cells at different stages along
the oligodendrolial lineage express opioid receptors, whose
modulation can induce both mitogenesis and differentiation
(Knapp et al., 1998; Persson et al., 2006; Eschenroeder
et al., 2012). These cells are also capable of synthesizing
opioids in a developmentally regulated manner (Knapp et al.,
2001). Cultured bipolar progenitors produce dynorphin, whose
expression is lost upon differentiation into mature OLs. In
contrast, proenkephalin-derived peptides are found in OPCs
and differentiated OLs (Knapp et al., 2001). Activation of
mu opioid receptor (MOR) in cultured OPC stimulates DNA
synthesis, whereas kappa opioid receptor inhibition increases
membrane extensions (Knapp et al., 1998). Although these
observations suggest that interference with the endogenous
opioid system affects OL maturation and myelination in the
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developing CNS, further studies will be needed to fully resolve
this question.
The growing use/abuse of opioids among younger persons
(Compton and Volkow, 2006; Calcaterra et al., 2013) poses
an especially high risk to pregnant addicts (in whom drug
effects could target early myelination in the fetus and newborn)
and adolescents and young adults (in whom late myelination
of cortical regions takes place). Prolonged administration of
morphine to neonatal rats is associated with increased neuronal
cell apoptosis in selective CNS areas (Bajic et al., 2013) and
leads to increased Toll-like receptor-4 and microglial activation
in adolescent rats (Schwarz and Bilbo, 2013). Heroin and
morphine abusers can suffer from leukoencephalopathy and
myelin loss (Chen et al., 2000; Nanan et al., 2000). Perinatal
exposure to therapeutic doses of methadone and buprenorphine
(used to treat opioid addiction) altered early myelination in
the developing rat brain (Eschenroeder et al., 2012; Vestal-
Laborde et al., 2014), with elevated brain levels of MBP,
PLP, andmyelin-oligodendrocyte glycoprotein. Not surprisingly,
these animals showed an increased number of axons with a
highly compacted myelin membrane. There was no parallel
reduction in the number of axons with a still uncompacted
myelin membrane, pointing to the existence of complex
drug effects. Methadone exerts direct effects at specific stages
of the OL lineage in vitro, stimulating the proliferation of
OPCs while accelerating maturation of more differentiated but
still immature preOLs (Vestal-Laborde et al., 2014). While
the long-term effects of these observations remain unknown,
accelerated or increased OL maturation and myelination
could disrupt the complex sequence of synchronized events
leading to normal connectivity in the developing brain.
These findings further point to a crucial function of the
endogenous opioid system in controlling OL development
and the timing of myelination, as well as the potential
for disrupting brain maturation at critical stages of myelin
formation.
The partial MOR agonist and kappa opioid receptor
antagonist buprenorphine merits special comment.
While treatment of mothers with therapeutic doses of methadone
results in accelerated and increased brain expression of mature
markers of OLs in pups, supra-therapeutic doses delayed MBP
expression and decreased the number of myelinated axons
(Eschenroeder et al., 2012). Buprenorphine anti-nociceptive
action also showed a biphasic bell-shaped curve, with low
doses being analgesic and higher doses loosing efficacy (Dum
and Herz, 1981; Lizasoain et al., 1991). Buprenorphine anti-
nociceptive effects are mediated by MOR and counteracted by
nociceptin (NOP) receptors (Lutfy et al., 2003). In the latter
study J-113397, a specific NOP receptor inhibitor, not only
enhanced the anti-nociceptive effect of buprenorphine but also
eliminated its bell-shaped response. This biphasic response was
not seen in NOP receptor knockout mice (Lutfy et al., 2003).
In OL cultures J-113397 abolished the biphasic dose-dependent
effect of buprenorphine on MBP expression (Eschenroeder et al.,
2012). The latter findings point to a crucial role for interactive
MOR and NOP receptor-mediated signaling in the timing of
OL maturation. Perinatal exposure to buprenorphine increases
the caliber of myelinated axons and with disproportionally
thinner myelin sheaths, possibly indicative of alterations in
axon-oligodendroglia/myelin interaction (Sanchez et al., 2008).
Exposure of rat pups to the MOR agonist methadone did not
cause these effects (Vestal-Laborde et al., 2014).
Prostaglandins
Cyclooxygenase (COX) catalyzes the rate-limiting step in the
synthesis of prostanoids from arachidonic acid (Smith et al.,
1996), and occurs as both constitutive (COX-1) and inducible
(COX-2) forms (Hewett et al., 2000). COX-2 expression
increases in CNS neurons in response to GluR activation
(Nogawa et al., 1997; Carlson, 2003), and its inhibition by
non-steroidal anti-inflammatory drugs and non-selective COX-
1/COX-2 inhibitors protects neurons from GluR-mediated
excitotoxic death in vitro (Hewett et al., 2000; Carlson,
2003) and in vivo (Nogawa et al., 1997). Transgenic mice
over-expressing neuronal COX-2 are more susceptible to
excitotoxicity (Kelley et al., 1999) and age-associated neuronal
cell loss (Andreasson et al., 2001). In contrast, COX-2-
deficient mice are more resistant to neuronal cell death caused
by ischemia or NMDA receptor activation (Iadecola et al.,
2001).
OLs and OPCs are more susceptible to excitotoxic death
following GluR-dependent COX-2 induction (Carlson et al.,
2010). COX-2 is expressed in dying OLs at the onset of
demyelination in Theiler’s murine encephalomyelitis virus
model of MS (Carlson et al., 2006) and in dying OLs in MS
lesions (Carlson et al., 2010). In the former case COX-2 inhibitors
reduced demyelination (Carlson et al., 2010). COX-2 contributes
to OL vulnerability also in the cuprizone model of demyelination
(Palumbo et al., 2012). COX-2 may thus have an important role
in demyelinating diseases like MS.
Prostanoids can contribute to excitotoxic death in OPCs
either via direct production by OPCs or activation of prostanoid
receptors on OPCs. Prostaglandin E2 (PGE2) synthesized by
OPCs in a GluR-dependent fashion engages EP3 subtype
receptors and contributes to excitotoxic death of OPCs (Carlson,
2003). In contrast, the EP2 receptor is protective (Carlson,
2003). Although EP1 receptor activation does not affect an OPC
excitotoxic challenge (Carlson et al., 2015), PGI2 can promote
OPC migration and remyelination in damaged areas (Takahashi
et al., 2013). Duringmyelination in developing rat brain, EP3 and
thromboxane A2 receptor are localized to the plasma membrane
and perinuclear membrane of OPCs, and their expression
levels—as well as thromboxane A2 synthesis—increase during
OLs maturation in concert with enhanced MBP expression
(Carlson et al., 2010).
Given the role of EP3 receptors in OPC excitotoxic death,
this receptor may be a potential therapeutic target for promoting
remyelination in demyelinating diseases such as MS.
Prolactin
PRL, originally described in the anterior pituitary gland plays
a role not only in reproduction, but also controls a variety of
behaviors and may participate in cell homeostasis, as well (Kelly
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et al., 1991; Freeman et al., 2000). Initially described in the
brain in hypothalamic axon terminals (Fuxe et al., 1977), PRL
immunoreactivity was later detected in telencephalon, cerebral
cortex, hippocampus, amygdala, septum (Devito, 1988), caudate
putamen (Harlan et al., 1989), brain stem (Devito, 1988; Harlan
et al., 1989), cerebellum (Seroogy et al., 1988), spinal cord
(Harlan et al., 1989; Siaud et al., 1989), choroid plexi, and
circumventricular organs (Thompson, 1982). The PRL receptor
belongs to class 1 of the cytokine receptor superfamily (Bazan,
1990a,b) whose gene shows widespread CNS expression.
PRL increases neurogenesis in the maternal mouse forebrain
during the first week of pregnancy, along with an increase
in OPC proliferation, OL generation, MBP expression and
ultimately, increased numbers of myelinated axons (Gregg
et al., 2007). PRL infused subcutaneously can mimic these
effects (Gregg et al., 2007). These observations suggest a
novel form of WM plasticity in the adult CNS and propose
that PRL may have therapeutic potential in treating WM
damage. At the same time, several reports suggest that PRL
can exert also an inflammatory role. In an animal model of
MS, the D2 agonists bromocriptine and dihydroergocryptine
reduced the PRL level and disease severity (Riskind et al.,
1991; Canonico et al., 1993; Zhornitsky et al., 2015). Although
PRL or PRL receptor knockout mice develop a delayed
onset experimental autoimmune encephalomyelitis but with full
clinical severity (Costanza et al., 2013) a small clinical trial failed
to demonstrate benefit of bromocriptine administration in MS
patients (Bissay et al., 1994). Thus, the therapeutic utility of
PRL in MS remains an open question; it would be interesting
to perform a trial combining PRL with an immunomodulator
(i.e., interferon-β commonly used in clinical practice; Zhornitsky
et al., 2015).
Cannabinoids
Cannabidiol (CBD), themost abundant cannabinoid inCannabis
sativa, is devoid of psychoactive properties and exerts anti-
inflammatory, antioxidant and neuroprotective effects (Izzo
et al., 2009). CBD is used for the treatment of inflammation, pain
and spasticity associated with MS (Sastre-Garriga et al., 2011).
Its biological effects are mediated through cannabinoid receptors
CB1 and CB2 (Howlett et al., 2002). The former is widely
expressed in CNS neurons, where it modulates neurotransmitter
release and synaptic plasticity regulated by Ca2+ andK+ channels
(Chevaleyre et al., 2006; Basavarajappa, 2007). CB2 receptor
expression is mainly, but not exclusively limited to immune cells
(Walter and Stella, 2004). OPCs and mature OLs both expess
CB1and CB2 receptors (Molina-Holgado et al., 2003; Benito et al.,
2007).
In rat optic nerve OLs, the CB1 receptor agonist arachidonoyl-
chloro-ethanolamide inhibited depolarization-induced Ca2+
influx (Mato et al., 2009). Similar effects were obtained with
the endocannabinoids anandamide and 2-arachidonoylglycerol
and the CB1 receptor agonist CP 55,940, but not the CB2
receptor agonist JWH133. In line with these findings CBD,
which acts also as a low-affinity CB1/CB2 receptor antagonist
raised [Ca2+]i concentration in OL primary cultures (Mato et al.,
2009, 2010) and was cytotoxic (Mato et al., 2010). However,
these [Ca2+]i changes appeared to be CB receptor-independent
(Mato et al., 2010). Given its lipophilic properties, it is
possible that CBD can directly affect [Ca2+]i stores. Not only
are mitochondria the main source of Ca2+ released from
CBD-stimulated OLs (Mato et al., 2010), but CB1 receptors
have been identified on brain mitochondrial membranes
(Hebert-Chatelain et al., 2014). In contrast, in neurons CBD
reduced [Ca2+]i influx and prevented apoptosis (Ryan et al.,
2009). The patho-physiological consequences of CBD action
may thus depend on the cellular context in which it is
expressed.
Nuclear Receptors
NRs are members of a large superfamily of evolutionarily
related transcription factors that regulate a broad spectrum of
physiological phenomena (Gronemeyer et al., 2004; Chambon,
2005; Evans, 2005). Each of the 48 NRs identified to date
has crucial and non-redundant roles, notably in biologically
important processes like growth, development, and homeostasis.
NRs modulate transcription through mechanisms which include
both activation and repression (Germain et al., 2006b). The NR
superfamily includes receptors for hydrophobic molecules
such as steroid hormones (e.g., estrogens, glucocorticoids
(GCs), progesterone, mineralocorticoids, androgens, vitaminD3,
ecdysone, oxysterols and bile acids), retinoic acids, TH, fatty
acids, leukotrienes and prostaglandins (Laudet and Gronemeyer,
2002).
Steroid Hormone Receptors
GCs are steroid hormones with recognized anti-inflammatory
properties. In the brain, two types of high-affinity receptors
bind GCs: the type I mineralocorticoid receptor (MR) and
the type II glucocorticoid receptor (GR; Vielkind et al., 1990).
Each receptor dimerizes with a GC-responsive element leading
to suppression of pro-inflammatory gene expression via block
of nuclear factor-kB or activator protein-1 (Trousson et al.,
2009). Both receptor types are widely expressed across neuronal
cell populations and glia, although the latter finding awaits
confirmation. Purified OLs and astrocytes from rat cerebrum and
cerebellum were shown to express differential levels of GR by
immunocytochemistry (Vielkind et al., 1990). At least in vitro,
all classes of glial cells express GRs that can translocate to the
nucleus in the presence of the cognate hormone ligand (Vielkind
et al., 1990).
Dexamethasone (DEX) alters OLs differentiation and
myelination in a developmental stage-specific manner. In
rat forebrain cell cultures DEX stimulated the early stages of
myelination but caused a markedly inhibition at later stages
(Almazan et al., 1986). When given systemically to 3-day-old
rats for 7 consecutive days DEX significantly decreased the
relative abundance of MBP and PLP mRNAs at P20 and P30 in
cerebrum, although in cerebellum MBP, PLP and glial fibrillary
acidic protein mRNAs decreased at P10 (Tsuneishi et al., 1991).
DEX thus appears to suppress expression of genes related to
glial functions, especially myelination, when administered in the
early postnatal period (Tsuneishi et al., 1991), notwithstanding
differences in susceptibility across brain areas.
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Sex Hormones
Sexual dimorphism in the brain vocal control area of the
songbird was first demonstrated four decades ago (Nottebohm
and Arnold, 1976). Magnetic resonance imaging shows
morphological differences in human cortical gray matter
volume (Gur et al., 1999) with females having larger volumes in
areas associated with language functions (Schlaepfer et al., 1995;
Harasty et al., 1997). In terms of WM differences between sexes,
men have larger overall WM relative to cerebral size (Goldstein
et al., 2001), while women appear to have larger WM volumes
involved in interhemisphere connectivity (Nopoulos et al., 2000).
Sexual dimorphism in rats was interpreted as a consequence
of the action of different sex hormones on brain development
(Cerghet et al., 2009).
We know relatively little concerning sexual dimorphism of
OLs and central myelin.WM volume (Gur et al., 1999), especially
in the corpus callosum (Fitch et al., 1990) is increased in males,
with females having more unmyelinated fibers. Yang et al. (2008)
later confirmed that WM volume, myelinated fiber volume and
volume of myelin sheaths in young rats are significantly larger in
males, although this ratio was reversed in middle-aged animals.
Differences in steroid hormone levels in developing animals
could account for sex differences inmyelination of axons through
hormone action on myelin protein expression (Jung-Testas and
Baulieu, 1998; Nuñez et al., 2000). It is also possible that sex
steroids could exert a protective effect onmyelin in developing, as
well as injured WM (De Nicola et al., 2006; Gerstner et al., 2007;
Garay et al., 2008).
Sexual differences in rodents are also manifested in terms
of OL myelin protein expression (Cerghet et al., 2009). Female
rodent OLs showed increased proliferation and death rate,
suggesting that their OLs have a shorter lifespan and more
rapid turnover. In male mice, castration increased glial cell
proliferation and decreased OL density (Cerghet et al., 2009).
Sex hormones, in particular testosterone, influence proliferation
and are potent inducers of remyelination (Hussain et al., 2013).
In enriched mouse OLs primary cultures, progesterone (P2),
estrogen (E2) and dihydrotestosterone (DHT) influenced total
cell number, proliferation and cell death independent of sex.
In particular, P2 significantly increased OL numbers (more so
in cultures from female mice), while E2 had a minor effect
and DHT reduced OL numbers in both sexes (Cerghet et al.,
2009).
Protein kinase B (Akt), MAPK and mammalian target of
rapamycin (mTOR) pathways are highly expressed inOLs (Flores
et al., 2000; Horiuchi et al., 2006) and represent, in relation to
cell survival/proliferation, possible biochemical targets for these
hormones (Hay, 2005; Chong et al., 2007). P2 caused a more
robust Akt up-regulation in OLs cultured from female mice in
comparison to male-derived cells, in line with effects of P2 on OL
numbers. Akt influences cell survival and proliferation through
downstream mTOR activation via transcriptional regulation
(Hay, 2005; Chong et al., 2007). P2 markedly increased mTOR
activity in an Akt-dependent manner, indicating a role for this
pathway in OL survival. As expected from its effects on OL
numbers, DHT reduced Akt activity in both sexes (Cerghet et al.,
2009). Interestingly, MAPK p42/p44 activation is involved in
excitotoxic cell death, mediated by Glu and pro-inflammatory
processes and leading to neurodegenerative diseases (Rosin et al.,
2004; Nikodemova et al., 2006). It is tempting to speculate that
by influencing proliferation and death of Ols, sex hormones may
contribute to differences in disease phenotype between male and
female MS patients.
Oxysterols and Liver X Receptors
The liver X receptor (LXR) is a member of the NR family
of transcription factors (Janowski et al., 1996) and is closely
related to NRs such as the peroxisome proliferator-activated
receptor (PPAR), farnesoid X receptor and retinoid X receptor
(RXR). Both LXR isoforms (α and β) are activated by oxysterols
originating from cholesterol oxidation (Freemantle et al., 2013).
OLs express LXR α and β which are crucial for cholesterol
homeostasis, a major lipid constituent of myelin sheaths. LXRs
are involved in myelination and remyelination processes. LXRα/β
double knockout mice exhibit altered motor coordination and
spatial learning, thinner myelin sheaths, and reduced myelin
gene expression in cerebellum. Conversely, activation of LXRs by
either 25-hydroxycholesterol or the agonist TO901317 stimulates
myelin gene expression at the promoter, mRNA, and protein
(PLP and MBP) levels. LXR activation also promotes OLs
cell maturation and remyelination after lysolecithin-induced
demyelination in organotypic cerebellar slice cultures. These
data strongly support a new role for LXRs as positive
modulators in central (re)myelination processes (Meffre et al.,
2015).
1,25-Dihydroxyvitamin D3
1,25-Dihydroxyvitamin D3 (1,25(OH)2D3) was initially
described to suppress experimental autoimmune
encephalomyelitis (Lemire and Archer, 1991; Spach et al., 2006)
through an anti-inflammatory mechanism. New data show
that 1,25(OH)2D3 can directly promote neural stem cell (NSC)
proliferation, survival and differentiation along the neuron and
OL, but not astrocyte, lineages. NSCs constitutively express
vitamin D receptor, which can be up-regulated by 1,25(OH)2D3.
NSCs treated with 1,25(OH)2D3 showed increased expression
of neurotrophic factors subserving neuronal cell survival and
differentiation (Shirazi et al., 2015).
Retinoic Acid and Retinoid X Receptor
The RXR (Prineas and Connell, 1979) is activated by 9-
cis retinoic acid (Patani et al., 2007), as well as 9-cis-13,14-
dihydro-retinoic acid (Raine andWu, 1993) and comprises three
isoforms: RXR-α, -β and -γ. RXRs work through heterodimeric
association with other NRs, such as retinoic acid receptors, TH
receptors, vitamin D receptors, PPARs and LXRs to regulate
cell proliferation, differentiation and apoptosis (Germain et al.,
2006a). RXR-γ is generally expressed at low levels in all glial
cell populations (Moreno et al., 2004) but is up-regulated in
activated microglia and macrophages, reactive astrocytes and
OLs after CNS injury (Schrage et al., 2006). RXR signaling
is associated with the CNS regenerative response and is
involved in the remyelination transcriptome (Huang et al., 2011).
The remyelination environment is composed of demyelinated
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axons, activated adult OPCs, regenerated OLs, microglia and/or
macrophages and reactive astrocytes (Franklin and ffrench-
Constant, 2008). Functional analyses in cultured OPCs using
RNA interference to knock down RXR-γ gene expression,
RXR-specific antagonists, as well as RXR-γ null mice showed
inefficient OL differentiation, indicating that RXR-γ is an
important regulator of remyelination (Huang et al., 2011).
The ability of RXR to form permissive or non-permissive
heterodimers with other NRs suggests that RXR can modulate
the expression of different genes, in a receptor- and context-
specific fashion (Altucci et al., 2007). Identification of which
nuclear receptor(s) heterodimerize with RXR-γ in OL lineage
cells after demyelination, and what genes are transcribed in
response to RXR-γ activation to promote the differentiation of
OPCs have remained open questions until now. However, a new
study by de la Fuente et al. (2015) provides data indicating that
RXR-γ binds to several NRs, including the vitamin D receptor, in
OPCs and mature OLs. These authors showed that inhibition of
vitamin D receptor signaling impaired OPC differentiation and
reduced the cells’ ability to remyelinate axons ex vivo. Vitamin D,
in contrast, boosted OPC differentiation (de la Fuente et al.,
2015).
Thyroid Hormone
TH actions are mediated mainly by T3 (Yen, 2001) which derives
by conversion of T4 to T3 via deiodinases. THs activate two
nuclear hormone receptor genes. The THR-α gene encodes
two isoforms (α1 and α2) while four additional isoforms are
encoded by the β gene (β1–4; Williams, 2000; Yen, 2001; Tagami
et al., 2010). THs play a critical role in oligodendrogenesis
and myelination. Acting through their cognate receptors, THs
promote expression of OL-specific genes includingMBP,myelin-
associated glycoprotein (MAG), PLP, and 2′,3′-cyclic nucleotide
3′-phosphodiesterase (CNPase) (Farsetti et al., 1991; Tosic
et al., 1992; Rodriguez-Pena et al., 1993). Studies using hypo-
and hyperthyroid animals as well as genetically modified
rodents clearly show that THs regulate OL differentiation and
maturation (Bernal, 2002; O’Shea and Williams, 2002; Zoeller
and Rovet, 2004; Dugas et al., 2012). In vitro, OPCs express
both THR-α and THR-β1; expression of the latter increases
with OL maturation (Barres et al., 1994; Gao et al., 1998).
GC-1, a thyromimetic with selective THR-β action (Chiellini
et al., 1998), promotes differentiation of both rodent and human
OPCs in vitro (Trost et al., 2000; Manzano et al., 2003).
Furthermore, GC-1 induces OL maturation during development
with increased production of MBP, CNPase and MAG (Baxi
et al., 2014).
OL differentiation can follow several distinct pathways,
including mitogen withdrawal and exposure to T3 (Barres et al.,
1993; Dugas et al., 2010), whereas OPC proliferation is induced
by PDGF (Barres et al., 1992). When exposed to T3 and PDGF,
OPCs continue to proliferate, differentiating only after multiple
rounds of cell division (Temple and Raff, 1986; Barres et al., 1994;
Durand and Raff, 2000). Like T3, GC-1 does not significantly
affect PDGF-induced OPC proliferation. Inappropriate OL
differentiation could thus deplete OPC numbers and hinder
myelination (Baxi et al., 2014).
PPAR-γ and 15-deoxy 12,14 Prostaglandin J2
The three known PPARs (PPAR-α, PPAR-β/δ and PPAR-γ)
belong to the superfamily of NRs. While ubiquitously expressed,
they also exhibit specific patterns of distribution. PPAR-
γ agonists exert anti-inflammatory, insulin-sensitizing and
neuroprotective effects, as well as promote the protection and
differentiation of OLs (Bernardo et al., 2009). In addition, PPAR-
γ agonists increase OL mitochondrial respiratory chain activity
and the cell’s ability to respond to environmental signals with
oscillatory Ca2+ waves. Both OL maturation and oscillatory
Ca2+ waves are prevented by the mitochondrial inhibitor
rotenone and restored by PPAR-γ agonists, suggesting that
PPAR-γ promotes myelination through mechanisms involving
mitochondria (Bernardo et al., 2009, 2013). Calcium signaling
plays an important role in OPC differentiation and myelination
(Soliven, 2001), process extension and migration (Simpson
and Armstrong, 1999; Yoo et al., 1999), and in retraction
of membrane sheets and cell death in mature mouse OLs
(Benjamins and Nedelkoska, 1996).
CONCLUSION AND PERSPECTIVES
The main functions of OLs in CNS are to provide support
and insulation to axons of some vertebrates, forming functional
units that allow the propagation of electrical signals. On
the other hand, neuronal activity regulates myelinating cell
development through signals that activate Ca2+-dependent
pathways (Butt, 2006). As discussed in this review, activation
is evoked by a wide range of membrane/intracellular receptors
or ion channels (for the latter, see Cheli et al., 2015) that
can induce an influx or release from intracellular stores,
increasing [Ca2+]i. To restore homeostasis, [Ca2+]i can be
sequestered into endoplasmic reticulum or extruded (Butt, 2006).
The balance between Ca2+ influx and efflux can determine
the temporal and special properties of OLs. Moreover, Ca2+
signaling in OPCs can influence not only differentiation
and myelination (Soliven, 2001), but also process extension
and migration (Simpson and Armstrong, 1999; Yoo et al.,
1999), and cell death in mature mouse OLs (Benjamins and
Nedelkoska, 1996). There is also evidence that oligodendroglia
exhibit Ca2+ transients in response to electrical activity
of axons for activity-dependent myelination (Wake et al.,
2015).
Failure of myelin development and oligodendrocyte loss
results in serious human disorders, includingMS. Understanding
how different neurotransmitters and hormones can regulate
[Ca2+]i, driving important effects on different stages of OPCs
development and specific molecular events could provide the
framework to facilitate the development of effective new
approaches in the therapeutic repair of myelin disorders that
complement established immunosuppressive approaches. In
this regard the landscape is beginning to show the fruits of
these investigations (Mullard, 2014; Ransohoff et al., 2015).
For example, several U.S. Food and Drug Administration-
approved drugs have shown promise in this direction, although
most are anticholinergics. Whether or not the other possible
pharmacological pathways are ineffective or have not been
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tried in not known. The antidyskinetic drug benztropine,
a selective M1 muscarinic acetylcholine receptor antagonist,
induced MBP expression in primary rat optic-nerve-derived
OPCs and decreased clinical severity in an experimental
autoimmune encephalomyelitis model of relapsing-remitting
MS when administered alone or in combination with the
approved immunosuppressive MS drugs FTY720 or interferon-β
(Deshmukh et al., 2013). However, potential dose-dependent
side-effects are associated with benztropine treatment in man
(Modell et al., 1989). Systemic treatment with the selective M3
antagonist solifenacin increased oligodendrocyte differentiation
of transplanted human OPCs in hypomyelinated shiverer/rag2
brain and enhanced functional repair (Abiraman et al.,
2015). Donepezil, an acetylcholinesterase inhibitor developed
for the treatment of Alzheimer’s disease, can stimulate
oligodendrocyte differentiation and maturation of NSC-derived
OPCs (Imamura et al., 2015). Importantly, neural precursor
cells have recently been demonstrated to make a major
contribution to remyelination in the cuprizone model of CNS
demyelination (Xing et al., 2014). Although some of the
reviewed pathways are involved in apoptosis (e.g., opioids,
acetylcholine), the PPAR-α agonist palmitoylethanolamide
(a fatty acid amide signaling molecule structurally related
to the endocannabinoid anandamide), presented as a co-
ultramicronized composite with the flavonoid luteolin is also
reported to promote OPC maturation (Barbierato et al., 2015).
Neither palmitoylethanolamide (Skaper et al., 2014) not luteolin
(Theoharides et al., 2012), at pharmacologically relevant doses,
has been reported to show adverse effects in man. While we
have focused on MS as an emblematic pathological condition
that could eventually benefit from OL-based repair therapies
for myelin loss, preventive treatment of premature infants with
drugs that accelerate the proliferation and/or maturation of
OPCs could reveal itself as the key to prevent an important cause
of mental retardation. No doubt the initial results discussed in
this review will encourage further progress in the years ahead.
SEARCH STRATEGY
A search for original articles focusing on OLs and
neurotransmitters and signaling was performed in PubMed
and SCOPUS. The search terms used were ‘‘oligodendrocyte’’,
‘‘myelin’’, ‘‘myelination’’, ‘‘oligodendrocyte precursor’’, ‘‘nuclear
receptor’’, ‘‘opioid’’, ‘‘glutamate’’, ‘‘GABA’’, ‘‘serotonin’’,
‘‘cholinergic’’, ‘‘muscarinic’’, ‘‘cannabinoid’’, ‘‘demyelination’’,
‘‘autoimmune’’, alone and in combination (other terms?). All
articles identified were English language (with the exception
of Virchow, R. 1854, originally written in German), full-text
articles. We also searched the reference lists of identified articles
for additional relevant articles.
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